Phase I Study of Gemcitabine Every Two Weeks
Author Information
Author(s): JB Vermorken, JP Guastalla, SR Hatty, DE Seitz, B Tanis, C McDaniels, MD Clavel
Primary Institution: University Hospital 'Vrije Universiteit', Amsterdam, Netherlands
Hypothesis
To determine the maximum tolerated dose (MTD) of gemcitabine using a once every 2 weeks schedule.
Conclusion
The study concluded that the once every 2 weeks schedule is not the most appropriate dosing schedule for gemcitabine, but it demonstrates a safety profile allowing for doses significantly higher than previously recommended.
Supporting Evidence
- The maximum tolerated dose (MTD) for the once every 2 weeks schedule was found to be 5700 mg m-2.
- Neutropenia was identified as the dose-limiting toxicity.
- One minor response was observed in a heavily pretreated breast cancer patient.
Takeaway
Doctors tested a new way to give a cancer medicine called gemcitabine to see how much they could safely give every two weeks. They found that patients could handle much higher doses than before.
Methodology
This was a phase I, dose-ranging, open-label, non-randomized study where gemcitabine was given as a 30-min infusion once every 2 weeks.
Limitations
The study was limited by the small sample size and the specific patient population with advanced refractory solid tumors.
Participant Demographics
52 patients (22 male, 30 female) aged 18-75 with advanced refractory solid tumors.
Want to read the original?
Access the complete publication on the publisher's website